Ziracin(TM). Everninomicin antibiotic

Drugs of the Future

Volumn 25, Issue 4, 2000, Pages 360-368

  Fromtling, Robert A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVERNIMICIN;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; NONHUMAN;

EID: 0034113856     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.04.571129     Document Type: Article

References (60)

1. Yao, J.D.C., Moellering, R.C. Jr. Antibacterial agents. In: Manual of Clinical Microbiology, 7th Edition, P.R. Murray, E.J. Barron, M.A. Pfaller, F.C. Tenover R.H. Yolken (Eds.), ASM Press, Washington DC, 1999, 1474-504.
2. Jones, R.N., Low, D.E., Pfaller, M.A. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant Gram-positive bacteria: The role of streptogramins and other newer compounds. Diagn Microbiol Infect Dis 1999, 33: 101-12.
3. Mollering, R.C. Jr. Introduction. A Symposium: Glycopeptide Resistance. Am J Med 1998, 104: 1-2S.
4. Pfaller, M.A., Jones, R.N., Marshall, S.A., Edmond, M.B., Wenzel, R.P. Nosocomial streptococcal bloodstream infections in the SCOPE program: Species occurrence and antimicrobial resistance. The SCOPE Hospital Study Group. Diagn Microbiol Infect Dis 1997, 29: 259-63.
5. Pfaller, M.A., Jones, R.N., Doern, G.V., Kugler, K. Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). The SENTRY Participants Group. Antimicrob Agents Chemother 1998, 42: 1762-70.
6. Centers for Disease Control. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. MMWR 1993, 42: 597-9.
7. Hiramatsu, K., Hanaki, H., Ino, T., Yabuta, K., Oguri, T., Tenover, E.C. Methicillin resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997, 40: 135-6.
8. Archer, G.L. Staphylococcus aureus: A well-armed pathogen. Clin Infect Dis 1998, 26: 1179-81.
9. Spera, R.V., Farber, B.F. Multidrug-resistant Enterococcus faecium. An untreatable nosocomial pathogen. Drugs 1994, 48: 678-88.
10. Swartz, M.N. Hospital acquired infections: Diseases with increasingly limited therapies. Proc Natl Acad Sci USA 1994, 91: 2420-7.
11. Tenover, F.C., Lancaster, M.V., Hill, B.C., Steward, C.D., Stocker, S.A., Hancock, G.A., O'Hara, C.M., Clark, N.C., Hiramatsu, K. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998, 36: 1010-27.
12. Baquero, F. Gram-positive resistance: Challenge for the development of new antibiotics. J Antimicrob Chemother 1997: 39(Suppl. A): 1-6.
13. Linden, P.K. Clinical implications of nosocomial Gram-positive bacteremia and superimposed antimicrobial resistance. Am J Med 1998, 104: 24-333.
14. Foster, D.R., Rybak, M.J. Pharmacologic and bacteriologic properties of SCH-27899 (Ziracin), an investigational antibiotic from the everninomicin family. Pharmacotherapy 1999, 19: 1111-7.
15. Weinstein, M.J., Luedemann, G.M., Oden, E.M., Wagman, G.H. Everninomicin, a new antibiotic complex from Micromonospora carbonacea. Antimicrob Agents Chemother 1964, 4: 24-32.
16. Black, J., Calesnick, B., Falco, F.G., Weinstein, M.J. Pharmacological properties of everninomicin D. Antimicrob Agents Chemother 1964, 4: 38-46.
17. Sanders, W.E. Jr., Sanders, C.C. Microbiological characterization of everninomicin B and D. Antimicrob Agents Chemother 1974, 6: 232-8.
18. Ganguly, A.K., Girijavallabhan, V.M., Miller, G.H., Sarre, O.Z. Chemical modification of everninomicin. J Antibiot 1982, 35: 561-70.
19. Waitz, J.A., Patel, M.G., Marquez, J.A., Kalyanpur, M.G., Heran, A.C (Schering Corp.). Antibiotic 13-384 complex from Micromonospora carbonacea var. africana. US 4597968.
20. Ganguly, A.K., Pramamk, R., Chan, T.M., Sarre, O., Liu, Y.T., Morton, J., Girijavallabhan, V. The structure of new oligosaccharide antibiotics 13-384 components 1 and 5. Heterocycles 1989, 28: 83.
21. Black, T.A., Zhao, W., Shaw, K.J., Hare, S. Physiological investigation on the mechanism of action of SCH 27399 (Ziracin). 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst C-106.
22. Adrian, P.V., Klugman, K.P. Ribosomal protein L16: The putative target site for everninomicin (SCH 27899) action in Streptococcus pneumoniae. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst C-110.
23. Adrian, P.V., Mendrick, C., Loebenberg, D., Shaw, K.J., Klugman, K.P., Hare, R.S., Black, T.A. Ziracin (SCH27899) inhibits a novel ribosome target site: An analysis of 23S rRNA mutants. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst 845.
24. McNicholas, P.M., Mann, P.A., Najarian, D.J., Miesel, L., Black, T.A., Hare, R.S., Shaw, K.J. Genetic and biochemical characterization of mutations in Staphylococcus aureus that result in reduced susceptibility to Ziracin (SCH 27899). 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst 846.
25. Loebenberg, D., Cacciapuoti, A., Naples, L., Moss, E.L. Jr., Menzel, F., Hare, R.S., Miller, G.H. Biological activity of SCH 27899 (EVE), an everninomicin antibiotic. 33rd Intersci Conf Antimicrob Agents Chemother (Oct 17-20, New Orleans) 1993, Abst 456.
26. Mortsell, E., Hagelberg, A., Dornbusch, K. In vitro activity of SCH 27899 on Clostridium difficile at various pHs. 33rd Intersci Conf Antimicrob Agents Chemother (Oct 17-20, New Orleans) 1993, Abst 457.
27. Bauernfeind, A., Jungwirth, R. In vitro activity of everninomicin (EVE) in comparison with vancomycin (VAN) and teicoplanin (TEI). 33rd Intersci Conf Antimicrob Agents Chemother (Oct 17-20, New Orleans) 1993, Abst 458.
28. Masmoudi, A., Caillon, J., Mazeau, C., Minozzi, C., Miller, G., Bismuth, R. In vitro antibacterial activity of everninomicin (SCH 27899) compared with vancomycin and teicoplanin against clinical isolates of staphylococci. 33rd Intersci Conf Antimicrob Agents Chemother (Oct 17-20, New Orleans) 1993, Abst 459.
29. Shlaes, D.M., Shlaes, J.H., Etter, L., Hare, R.S., Miller, G.H. SCH-27899 (EVE), an everninomicin active against multiply-resistant enterococci and staphylococci. 33rd Intersci Conf Antimicrob Ager. Chemother (Oct 17-20, New Orleans) 1993, Abst 460.
30. Nakashio, S., Iwasawa, H., Hori, S., Shimada, J. Comparative antimicrobial activity of everninomicin (SCH 27899), a new oligosaccharide antibiotic, against resistant clinical isolates. 33rd Intersci Conf Antimicrob Agents Chemother (Oct 17-20, New Orleans) 1993, Abst 461.
31. Nishino, T., Sakurai, M. In vitro activity of everninomicin (SCH 27899). 33rd Intersci Conf Antimicrob Agents Chemother (Oct 17-20, New Orleans) 1993, Abst 462.
32. Urban, C., Mariano, N., Mosinkasnipas, K., Wadee, C., Chahrour, T., Rahal, J.J. Comparative in vitro activity of SCH 27899, a novel everninomicin. 33rd Intersci Conf Antimicrob Agents Chemother (Oct 17-20, New Orleans) 1993, Abst 463.
33. Goto, S., Yamaguchi, K., Kaneko, Y., Tsuji, A., Miyazaki, S. In vitro antibacterial activities of everninomicin (SCH 27899), a novel oligosaccharide antibiotic. 33rd Intersci Conf Antimicrob Agents Chemother (Oct 17-20, New Orleans) 1993, Abst 464.
34. Chin, N.X., Neu, H.C. In vitro activity of SCH 27899 against aerobic and anaerobic Gram-positive bacteria. 33rd Intersci Conf Antimicrob Agents Chemother (Oct 17-20, New Orleans) 1993, Abst 465.
35. Boyce, J.M., Medeiros, A.A. In vitro activity of SCH27899 against multi-drug resistant Gram-positive cocci (MDP-GPC). 33rd Intersci Conf Antimicrob Agents Chemother (Oct 17-20, New Orleans) 1993, Abst 466.
36. Jones, R.N., Barrett, M.S., Erwin, M.E. In vitro evaluations of everninomicin (SCH 27899), a novel antimicrobial agent with a wide spectrum against clinically important Gram-positive pathogens. 34th Intersci Conf Antimicrob Agents Chemother (Oct 4-7, Orlando) 1994, Abst F126.
37. Urban, C., Mariano, N., Mosinka-Snipas, K., Wadee, C., Chahrour, T., Rahal, J.J. Comparative in vitro activity of SCH 27899, a novel everninomicin, and vancomycin. J Antimicrob Chemother 1996, 37: 361-4.
38. Jones, R.N., Marshall, S.A., Erwin, M.E. Antimicrobial activity and spectrum of SCH27899 (Ziracin®) tested against Gram-positive species including recommendations for routine susceptibility testing methods and quality control. Diagn Microbiol Infect Dis 1999, 34: 103-10.
39. Marshall, S.A., Jones, R.N., Erwin, M.E. Antimicrobial activity of SCH27899 (Ziracin), a novel everninomicin derivative, tested against Streptococcus spp.: Disk diffusion/Etest method evaluations and quality control guidelines. Diagn Microbiol Infect Dis 1999, 33: 19-25.
40. Fuchs, P.C., Barry, R.L., Brown, S.D. In vitro activities of SCH 27899 alone and in combination with 17 other antimicrobial agents. Antimicrob Agents Chemother 1999, 43: 2996-7.
41. Miyazaki, S., Ishii, Y., Ohno, A., Furuya, N., Matsumoto, T., Tateda, K., Yamaguchi, K. In vitro activities of 11 antibiotics against vancomycin-resistant enterococci isolated in Japan. J Antimicrob Chemother 1999, 44: 415-6.
42. Dever, L., Torigian, C.V., Barbour, A. In vitro activities of the everninomicin SCH 27899 and other newer antimicrobial agents against Borrelia burgdorferi. Antimicrob Agents Chemother 1999, 43: 1773-5.
43. Edelstein, P.H., Edelstein, M.A.C. In vitro activity of SCH 27899 (Ziracin) against Legionella species. Diagn Microbiol Infect Dis 1999, 33: 59-62.
44. Takemura, H., Ikejima, H., Kunishima, H., Terakubo, K., Kanemitsu, K., Yamamoto, H., Kaku, M., Shimada, J. Evaluation of antimicrobial activities of SCH27899 (everninomicin) for Legionella spp. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst 1927.
45. Zbaida, S., Brieland, J., Krieter, P., Loebenberg, D., Horne, D., Lu, X., Yuan, Y., Hare, R., Cayen, M.N., Patrick, J. In vitro uptake of Ziracin (SCH 27899) by rat alveolar macrophages. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst 1928.
46. Bauernfeind, A., Eberlein, E., Jungwirth, R. Comparative bactericidal kinetics of everninomicin (SCH 27899) at various dosages in a pharmacodynamic model. 37th Intersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst A-30.
47. Menzel, F. Jr., Norris, C., Michalski, M., Corcoran, E., Moss, E.L. Jr., Cacciapuoti, A.F., Loebenberg, D., Hare, R.S., Miller, G.H. Efficacy of SCH 27899 (Ziracin) against bacterial infections in mice. 37th Intersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst B-98.
48. Wang, E., Bergeron, Y., Simard, M., Cote-Richer, M., Bergeron, M.G. Efficacy of Ziracin (SCH 27899) in a mouse model of pneumococcal pneumonia. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst B-40.
49. Wang, E., Simard, M., Bergeron, Y., Beauchamp, D., Bergeron, M.G. In vivo activity and pharmacokinetics of Ziracin (SCH27899), a new long-acting everninomicin antibiotic, in a murine model of penicillin-susceptible or penicillin-resistant pneumococcal pneumonia. Antimicrob Agents Chemother 2000, 44: 1010-8.
50. Brieland, J.K., Loebenberg, D., Menzel, F., Cacciapuoti, A., Hare, R. Efficacy of Ziracin (SCH 27899), a new everninomicin antibiotic, against a replicative Legionella pneumophilia lung infection in mice. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst B-44.
51. Tomono, K., Tomiyama, Y., Hirakata, Y., Maesaki, S., Tashiro, K., Kohno, S. In vivo activities of SCH27899 (Ziracin) in a murine model of hematogenous pulmonary infection induced by Staphylococcus aureus enmeshed in agar beads. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst B-43.
52. Fang, G.D., Loebenberg, D., Scheld, W.M. Comparative efficacy of Ziracin (SCH 27899, ZIR) in highly penicillin-resistant Streptococcus pneumoniae (PRSP) experimental meningitis in rabbits. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst 1786.
53. Lin, C., Nomeir, A., Lim, J., Loebenberg, D., Hare, R., Miller, G.H. Pharmacokinetics of everninomicin (SCH 27899) in mice, rats, rabbits and cynomolgus monkeys. 34th Intersci Conf Antimicrob Agents Chemother (Oct 4-7, Orlando) 1994, Abst F128.
54. Lin, C., Gupta, S., Loebenberg, D., Cayen, M.N. Pharmacokinetics of an everninomicin (SCH 27899) in mice, rats, rabbits, and cynomolgus monkeys following intravenous administration. Antimicrob Agents Chemother 2000, 44: 916-9.
55. Krieter, P., Thonoor, M., Wirth, M., Gupta, S., Patrick, J., Cayen, M.N. Pharmacokinetics and metabolism of 14C-SCH 27899 (Ziracin) in rats and monkeys. 37th Intersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst A-112.
56. Menon, S., Pal, S., Banfield, C., Cayen, M., Affrime, M.B., Batra, V. Effect of gender on the pharmacokinetics of Ziracin (SCH 27899) in healthy volunteers. 37th Intersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst A-113.
57. Banfield, C.R., Glue, P., Affrime, M.B., Flannery, B.F., Pai, S., Menon, S., Batra, V., Rudewicz, P. Multiple-dose safety, tolerance and pharmacokinetics of Ziracin (SCH 27899): A new, novel oligosaccharide antibiotic. 37th Intersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst A-114.
58. Banfield, C., Pai, S., Swan, S.K., Lambrecht, L., Laughlin, M., Affrime, M. Effect of renal insufficiency on the single-dose pharmacokinetics (PK) of SCH 27899 (Ziracin). 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst A-50.
59. Krieter, P., Banfield, C., Thonoor, M., Blumenkrantz, N., Chowdhury, S., Musick, T., Pai, S., Batra, V., Cayen, M., Patrick, J. Pharmacokinetics, metabolism and excretion of 14C-Ziracin (SCH27899) in healthy male volunteers. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26-29, San Francisco) 1999, Abst 1196.
60. Tsitsi, J.M.L., Calver, A.D., Luke, B., Garaud, J-J., Grint, P. Gupte, J., Wherry, J.C.R. A double-blind, randomized, multicenter study of Ziracin versus ceftriaxone in patients with S. pneumoniae pneumonia. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst L-109.